格隆汇7月29日｜药明康德(603259)：将回购股份价格上限由不超过90.72元/股(含)调整为不超过人民币 114.15元/股，回购方案其他内容不变。 (责任编辑：宋政 HN002) 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com ...

药明康德H股7月以来累计上涨逾42%，年内涨幅超103%，表现更胜A股。 股价大涨背后是公司坚实的业绩表现——药明康德7月28日晚间发布的2025年半年报显示，上半年公司 营收达208亿元，同比增长20.64%；净利润达85.6亿元，同比增长101.92%，创上市以来最佳半年表现； 扣非净利55.82亿元，同比增长26.47%；毛利率提升至44.45%，亦创上市以来半年报数据最高纪录。 靓丽的半年报发布后，多家外资投行就药明康德发布研报上调公司目标价。 转自：新华财经 新华财经上海7月29日电（林郑宏）7月29日，A股三大股指延续涨势，沪指收盘站上3600点整数关口， 收盘点位创年内新高；深成指涨0.64%，创业板指大涨1.86%，自去年11月13日后收盘点位首次突破 2400点整数关口。 医药股成为推动创业板指上涨的主要动力，CXO、减肥药、创新药等概念板块领涨两市，其中CXO板 块涨幅居首。成交额超过10亿元的8只行业主题类ETF中，易方达沪深300医药ETF（512010）上涨 2.68%，成交13.63亿元，位列第4；华宝中证医疗ETF（512170）上涨2.45%，成交11.52亿元，位列第 7。 ...

证券代码：603259 证券简称：药明康德 公告编号：临 2025-052 无锡药明康德新药开发股份有限公司 1 年 6 月 25 日披露的《关于 2025 年第一次以集中竞价交易方式回购 A 股股份的 回购报告书》（公告编号：临 2025-042）。 二、回购股份的进展情况 截至 2025 年 7 月 28 日，公司在本次回购方案下累计通过集中竞价交易方 式回购 A 股股份 6,514,425 股，占公司总股本的 0.23%，回购最高价格为人民币 90.70 元/股，回购最低价格人民币 65.53 元/股，回购价格均价人民币 76.34 元/ 股，使用资金总额人民币 497,297,934.64 元（不含交易费用）。 关于调整回购股份价格上限的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 无锡药明康德新药开发股份有限公司（以下简称"公司"）于 2025 年 7 月 29 日召开第三届董事会第二十三次会议，审议通过了《关于调整回购股份价 格上限的议案》，公司拟将 2025 年第一次以集中竞价交易方式回购 ...

Market Overview - The Hang Seng Index closed at 25,524.45, down by 0.15%, while the Hang Seng China Enterprises Index fell by 0.34% to 9,145.92. The Hang Seng Tech Index decreased by 0.35% to 5,644.38, with intraday declines reaching 1.2% for the first two indices and a significant drop of 2% for the tech index [1] - Despite the index adjustments, southbound capital saw a substantial net purchase of Hong Kong stocks exceeding 10 billion HKD [1] Stock Performance - Notable gainers in the biopharmaceutical sector included WuXi AppTec (up 11.25%), with other companies like CSPC Pharmaceutical and Green Leaf Pharmaceutical also showing strong performance, rising over 8% [3] - The top-performing stocks included WuXi Biologics-B (up 33.33%), Chuangsheng Group-B (up 17.06%), and Dongyao Pharmaceutical-B (up 15.06%) [2] Sector Trends - Large tech stocks showed a narrowing of losses in the afternoon, with Alibaba slightly turning positive, while Tencent, JD.com, Meituan, and Kuaishou experienced declines within 1%. Xiaomi fell by 2.6%, and Baidu dropped nearly 2% [3] - The "anti-involution" sectors, including steel and photovoltaic stocks, saw a rebound, while sectors like banking, catering, and robotics generally declined [3]

人民财讯7月29日电，药明康德（603259）7月29日晚间公告，拟将2025年第一次以集中竞价交易方式回 购A股股份的回购股份价格上限由不超过90.72元/股（含）调整为不超过114.15元/股，本次回购方案的 其他内容不变。 ...

"10倍股"上纬新材（688585）今天盘中股价再创历史新高，但走势波动较大。该股今天上涨6.19%，今年以来累计涨1169%。 上午，上纬新材一度涨近18%，午后股价缓慢回落，13:42左右，股价突然直线跳水翻绿，后又大幅拉升，一度涨超15%，临近尾盘，股价再度跳水。今 天，上纬新材成交额超21亿元。 算力和创新药板块走强 近期，算力、创新药及其上游的CXO板块持续走强。今天，这两大板块再度大涨。 CRO板块今天领涨，睿智医药、药石科技等个股大涨。两大龙头股药明康德、恒瑞医药分别上涨7.72%、2.84%。 7月29日，A股三大指数全线飘红，创业板指站上2400点。 截至收盘，上证指数上涨0.33%，深证成指上涨0.64%，创业板指上涨1.86%，报2406.59点。全市场成交额约1.83万亿元。 上纬新材巨震 一是各板块的龙头股持续走强，每天都有不少龙头股刷新历史新高。今天，新易盛、中际旭创、生益科技、胜宏科技、仕佳光子、沪电股份、工业富联、 苑东生物、益方生物、芯碁微装、电气风电等个股盘中股价创历史新高。 二是市场更加聚焦大市值和中市值的龙头股。 | | | 874.62 4.00% | | | | - ...

截至收盘，上证指数上涨0.33%，深证成指上涨0.64%，创业板指上涨1.86%，报2406.59点。全市场成交额约1.83万亿元。 上纬新材巨震 "10倍股"上纬新材（688585）今天盘中股价再创历史新高，但走势波动较大。该股今天上涨6.19%，今年以来累计涨1169%。 7月29日，A股三大指数全线飘红，创业板指站上2400点。 上午，上纬新材一度涨近18%，午后股价缓慢回落，13:42左右，股价突然直线跳水翻绿，后又大幅拉升，一度涨超15%，临近尾盘，股价再度跳水。今 天，上纬新材成交额超21亿元。 算力和创新药板块走强 近期，算力、创新药及其上游的CXO板块持续走强。今天，这两大板块再度大涨。 CRO板块今天领涨，睿智医药、药石科技等个股大涨。两大龙头股药明康德、恒瑞医药分别上涨7.72%、2.84%。 | | | 874.62 4.00% | | | | --- | --- | --- | --- | --- | | 成分股 | 基金 | 资金 | 板块分析 | 新闻 | | ●展开分析 | | 最新 | 涨幅 ◆ | 流通市值 | | 睿智医药 | | 13.61 | 20.02% | 67.7 ...

（文章来源：每日经济新闻） 每经AI快讯，7月29日，药明康德公告，将回购股份价格上限由不超过90.72元/股（含）调整为不超过 114.15元/股，回购方案其他内容不变。 ...

Group 1: Market Performance - The three major A-share indices collectively rose, with the Shenzhen Component Index and the ChiNext Index reaching new highs for the year. The Shanghai Composite Index increased by 0.33%, closing above 3600 points, while the Shenzhen Component Index rose by 0.64% and the ChiNext Index by 1.86%. The total trading volume in the Shanghai and Shenzhen markets reached 1.8032 trillion yuan, an increase of 60.9 billion yuan compared to the previous day [1]. Group 2: Innovation Drug Sector - The Hong Kong innovation drug index has more than doubled since the beginning of the year, achieving a growth of over 105% [2][3]. - WuXi AppTec reported a revenue of 20.799 billion yuan for the first half of 2025, a year-on-year increase of 20.64%, with net profit reaching 8.56 billion yuan, marking a 101.92% increase. The company also announced its first-ever interim dividend plan, proposing a cash dividend of 3.5 yuan per 10 shares, totaling approximately 1 billion yuan [5]. - The total amount of outbound licensing for Chinese innovative drugs has surged, with a report indicating that the total amount for the first half of 2025 has approached 66 billion dollars, surpassing the total for the entire year of 2024 [5]. Group 3: CPO Sector - The CPO and computing hardware stocks showed strong performance, with Zhongji Xuchuang rising over 9% and reaching a historical high. The sector has remained active since mid-July, following Nvidia's announcement regarding H20 [6][9]. - Huawei showcased its Ascend 384 super node at the World Artificial Intelligence Conference, which integrates 384 Ascend 910C NPUs and 192 Kunpeng CPUs, achieving a computing power of 300 Pflops, surpassing Nvidia's NVL72 system [9]. Group 4: Maternal and Infant Industry - The maternal and infant industry saw a collective rise, particularly in the dairy sector, following the announcement of a child-rearing subsidy of 3600 yuan per child per year for children under three years old [10][11]. - Although the subsidy does not fully cover the average annual cost of raising a child, which is approximately 25,000 yuan, it signals significant policy support. The estimated fiscal input for 2024 based on projected birth rates is around 30 billion yuan [12]. - The subsidy is expected to boost consumption in the dairy sector, particularly in milk powder, and enhance market confidence as more birth-related policies are implemented [14].

Core Viewpoint - The company reported strong financial performance for H1 2025, driven by high demand in the TEDIS business, leading to an upward revision of its annual performance guidance [1][4]. Group 1: Financial Performance - In H1 2025, the company achieved revenue of 20.8 billion yuan, a year-on-year increase of 20.6%, with continuous operations revenue growing by 24.2% [1]. - Adjusted net profit attributable to shareholders reached 6.31 billion yuan, up 44.4% year-on-year, while the net profit attributable to shareholders was approximately 8.56 billion yuan, reflecting a 101.9% increase [1]. - For Q2 2025, the company reported revenue of 11.14 billion yuan, a 20.4% year-on-year growth, and adjusted net profit of 3.64 billion yuan, up 47.9% [1]. Group 2: Business Segments - **Chemical Business (WuXi Chemistry)**: H1 2025 revenue was 16.3 billion yuan, a 33.5% increase, with an adjusted gross margin of 49.0%, up 5.2 percentage points. The TIDES business saw revenue of 5.03 billion yuan, a significant 141.6% increase [2]. - **Testing Business (WuXi Testing)**: H1 2025 revenue was 2.69 billion yuan, a slight decline of 1.2%, with an adjusted gross margin of 25.1%, down 12.3 percentage points. Q2 2025 showed signs of recovery with a 5.5% year-on-year growth in laboratory analysis and testing services [3]. - **Biology Business (WuXi Biology)**: H1 2025 revenue was 1.25 billion yuan, a 7.1% increase, with an adjusted gross margin of 36.4%, down 0.7 percentage points. The business contributed to over 30% of new customer acquisition [4]. Group 3: Market Dynamics - The company has a strong international presence, with approximately 85% of revenue coming from overseas clients. Revenue from U.S. clients was 14.03 billion yuan, up 38.4%, while revenue from Chinese clients decreased by 5.2% to 3.15 billion yuan [5]. - The company’s order backlog for continuous operations reached 56.69 billion yuan, a 37.2% year-on-year increase, indicating robust future growth potential [4]. Group 4: Future Outlook - The company has revised its 2025 revenue growth target for continuous operations from 10-15% to 13-17%, with overall revenue targets adjusted from 41.5-43 billion yuan to 42.5-43.5 billion yuan [4]. - The company expects to maintain strong growth trends in the second half of 2025, supported by high demand in the TEDIS business [4].